Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Post by 4Justiceon Jan 21, 2022 8:41am
254 Views
Post# 34341425

ARMISTICE CATCH UP AGAIN

ARMISTICE CATCH UP AGAINARMISTICE is one of the ten big funds which togeder represent more than 50% of Zymeworks. They have skin in the game. Unfortunately ARMISTICE was cheated  in its deal with Liminal whose CEO was Galbraith with Klompas on the board. First bad review! Now ARMISTICE is for the second time in bad position with a CEO who never had skin in the game and never deliver the goods.

ARMISTICE wake up before loosing again the money of your investors and your credibility. You are screwed for a second time.
<< Previous
Bullboard Posts
Next >>